-
care. BCI is also a partner in the CRUK City of London Major Centre (together with UCL, Kings and the Francis Crick Institute) which is a Centre of Excellence in Biotherapeutics. About Queen Mary
-
resistance in colorectal cancer. We use single-cell multiomics and spatial transcriptomics data from patient samples and patient-derived organoids (Ogden et al., Cell Genomics 2025, Efremova et al. Nature
-
improvements in cancer patient care. BCI is also a partner in the CRUK City of London Major Centre (together with UCL, Kings and the Francis Crick Institute) which is a Centre of Excellence in Biotherapeutics
-
care. BCI is also a partner in the CRUK City of London Major Centre (together with UCL, Kings and the Francis Crick Institute) which is a Centre of Excellence in Biotherapeutics. BCI is committed in
-
(together with UCL, King’s and the Francis Crick Institute) which is a Centre of Excellence in Biotherapeutics. BCI is committed in supporting and developing future cancer researchers through its extensive
-
the Centre for Experimental Cancer Medicine and the Barts NHS Trust to achieve improvements in cancer patient care. BCI is also a partner in the CRUK City of London Major Centre (together with UCL, Kings and
-
use a series of model systems with increasing complexity, including patient derived spheroids, to recreate the breast tissue during obesity we study cellular metabolism via our dedicated MS facility. In